253 related articles for article (PubMed ID: 12703963)
21. Sequence selectivity, cross-linking efficiency and cytotoxicity of DNA-targeted 4-anilinoquinoline aniline mustards.
McClean S; Costelloe C; Denny WA; Searcey M; Wakelin LP
Anticancer Drug Des; 1999 Jun; 14(3):187-204. PubMed ID: 10500495
[TBL] [Abstract][Full Text] [Related]
22. Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
Hay MP; Atwell GJ; Wilson WR; Pullen SM; Denny WA
J Med Chem; 2003 Jun; 46(12):2456-66. PubMed ID: 12773049
[TBL] [Abstract][Full Text] [Related]
23. Prodrugs for Nitroreductase Based Cancer Therapy- 1: Metabolite Profile, Cell Cytotoxicity and Molecular Modeling Interactions of Nitro Benzamides with Ssap-NtrB.
Gungor T; Yetis G; Onder FC; Tokay E; Tok TT; Celik A; Ay M; Kockar F
Med Chem; 2018; 14(5):495-507. PubMed ID: 29189173
[TBL] [Abstract][Full Text] [Related]
24. Nitroimidazole-based "extruded mustards' designed as reductively activated hypoxia-selective cytotoxins.
Hay MP; Denny WA; Wilson WR
Anticancer Drug Des; 1996 Jul; 11(5):383-402. PubMed ID: 8765531
[TBL] [Abstract][Full Text] [Related]
25. Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy.
Friedlos F; Denny WA; Palmer BD; Springer CJ
J Med Chem; 1997 Apr; 40(8):1270-5. PubMed ID: 9111301
[TBL] [Abstract][Full Text] [Related]
26. Aerobic 2- and 4-nitroreduction of CB 1954 by human liver.
Tang MH; Helsby NA; Wilson WR; Tingle MD
Toxicology; 2005 Dec; 216(2-3):129-39. PubMed ID: 16129536
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
Jiang Y; Han J; Yu C; Vass SO; Searle PF; Browne P; Knox RJ; Hu L
J Med Chem; 2006 Jul; 49(14):4333-43. PubMed ID: 16821793
[TBL] [Abstract][Full Text] [Related]
28. Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT.
Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Lehouritis P; Marais R; Springer CJ
J Med Chem; 2003 Apr; 46(9):1690-705. PubMed ID: 12699387
[TBL] [Abstract][Full Text] [Related]
29. Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems.
Niculescu-Duvaz I; Scanlon I; Niculescu-Duvaz D; Friedlos F; Martin J; Marais R; Springer CJ
J Med Chem; 2004 May; 47(10):2651-8. PubMed ID: 15115406
[TBL] [Abstract][Full Text] [Related]
30. DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.
Singleton RS; Guise CP; Ferry DM; Pullen SM; Dorie MJ; Brown JM; Patterson AV; Wilson WR
Cancer Res; 2009 May; 69(9):3884-91. PubMed ID: 19366798
[TBL] [Abstract][Full Text] [Related]
31. 1,2-benzisoxazole phosphorodiamidates as novel anticancer prodrugs requiring bioreductive activation.
Jain M; Kwon CH
J Med Chem; 2003 Dec; 46(25):5428-36. PubMed ID: 14640551
[TBL] [Abstract][Full Text] [Related]
32. Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines.
Palmer BD; Wilson WR; Pullen SM; Denny WA
J Med Chem; 1990 Jan; 33(1):112-21. PubMed ID: 2296009
[TBL] [Abstract][Full Text] [Related]
33. Virus-directed enzyme prodrug therapy using CB1954.
Grove JI; Searle PF; Weedon SJ; Green NK; McNeish IA; Kerr DJ
Anticancer Drug Des; 1999 Dec; 14(6):461-72. PubMed ID: 10834268
[TBL] [Abstract][Full Text] [Related]
34. Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.
Tercel M; Wilson WR; Anderson RF; Denny WA
J Med Chem; 1996 Mar; 39(5):1084-94. PubMed ID: 8676343
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia-activated prodrugs: substituent effects on the properties of nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (nitroCBI) prodrugs of DNA minor groove alkylating agents.
Tercel M; Atwell GJ; Yang S; Stevenson RJ; Botting KJ; Boyd M; Smith E; Anderson RF; Denny WA; Wilson WR; Pruijn FB
J Med Chem; 2009 Nov; 52(22):7258-72. PubMed ID: 19877646
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and structure-activity relationships of nitrobenzyl phosphoramide mustards as nitroreductase-activated prodrugs.
Hu L; Wu X; Han J; Chen L; Vass SO; Browne P; Hall BS; Bot C; Gobalakrishnapillai V; Searle PF; Knox RJ; Wilkinson SR
Bioorg Med Chem Lett; 2011 Jul; 21(13):3986-91. PubMed ID: 21620697
[TBL] [Abstract][Full Text] [Related]
37. Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
Hu L; Yu C; Jiang Y; Han J; Li Z; Browne P; Race PR; Knox RJ; Searle PF; Hyde EI
J Med Chem; 2003 Nov; 46(23):4818-21. PubMed ID: 14584930
[TBL] [Abstract][Full Text] [Related]
38. DNA-directed alkylating agents. 1. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the reactivity of the mustard.
Gourdie TA; Valu KK; Gravatt GL; Boritzki TJ; Baguley BC; Wakelin LP; Wilson WR; Woodgate PD; Denny WA
J Med Chem; 1990 Apr; 33(4):1177-86. PubMed ID: 2319563
[TBL] [Abstract][Full Text] [Related]
39. Mechanism of CB1954 reduction by Escherichia coli nitroreductase.
Christofferson A; Wilkie J
Biochem Soc Trans; 2009 Apr; 37(Pt 2):413-8. PubMed ID: 19290872
[TBL] [Abstract][Full Text] [Related]
40. E. coli nitroreductase/CB1954 gene-directed enzyme prodrug therapy: role of arylamine N-acetlytransferase 2.
Mitchell DJ; Minchin RF
Cancer Gene Ther; 2008 Nov; 15(11):758-64. PubMed ID: 18600257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
